Research programme: tuberculosis therapies - Sanofi

Drug Profile

Research programme: tuberculosis therapies - Sanofi

Alternative Names: TB therapies - Sanofi/Global Alliance for TB Drug Development (TB Alliance); TB therapies - Sanofi/Weill Cornell Medical College

Latest Information Update: 26 Sep 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Developer Global Alliance for TB Drug Development; Sanofi
  • Class Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Tuberculosis

Most Recent Events

  • 20 Sep 2012 Sanofi and Global Alliance for TB Drug Development entered a new collaborative agreement to accelerate discovery and development of new Tuberculosis therapies
  • 29 Jun 2011 Early research is ongoing in USA
  • 29 Jun 2011 Sanofi and Weill Cornell Medical College are collaborating on the development in the US of compounds to treat tuberculosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top